Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus

OBJECTIVES: SLE is an autoimmune disease characterised by aberrant lymphocyte activation and autoantibody production. This study provides an in-depth preclinical and clinical characterisation of the treatment effect of cenerimod, a sphingosine-1-phosphate receptor type 1 (S1P(1)) modulator, in SLE....

Descripción completa

Detalles Bibliográficos
Autores principales: Strasser, Daniel S, Froidevaux, Sylvie, Sippel, Virginie, Gerossier, Estelle, Grieder, Ursula, Pierlot, Gabin M, Kieninger-Graefitsch, Andrea, Vezzali, Enrico, Stalder, Anna K, Renault, Bérengère, Ryge, Jesper, Hart, Aaron, Mentzel, Ulrich, Groenen, Peter M A, Keller, Marcel P, Trendelenburg, Marten, Martinic, Marianne M, Murphy, Mark J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Lupus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722385/
https://www.ncbi.nlm.nih.gov/pubmed/32917831
http://dx.doi.org/10.1136/rmdopen-2020-001261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722385/
https://www.ncbi.nlm.nih.gov/pubmed/32917831
http://dx.doi.org/10.1136/rmdopen-2020-001261

Ejemplares similares